Categories
Change Password!
Reset Password!
Mesotherapy relieves chronic pain and neuropathic symptoms following COVID-19 infection.
Published in Clinical Therapeutics, a recent study explored whether Mesotherapy provides superior relief compared to traditional oral treatments.
A retrospective review comprising of 96 post-COVID pain syndrome patients was conducted by İlknur Topal and Onur Yılmaz. Patients were divided into two groups, one received oral therapy with Diclofenac, Thiocolchicoside, and Cyanocobalamin (number of patients = 46), whereas the other received Mesotherapy intradermally with Lidocaine 2% and Cyanocobalamin (number of patients = 50). Pain and neuropathic symptoms were assessed using the Visual Analogue Scale and Leeds Assessment of Neuropathic Symptoms and Signs scales before and one week after treatment.
No notable discrepancies were observed in the pain scale outcomes before the treatment in either of the groups. Post-treatment, both groups showed improvement, but Mesotherapy led to considerably greater reductions in VAS and LANSS scores compared to oral therapy.
Mesotherapy is a more effective and better-tolerated treatment for pain syndrome following SARS-CoV-2 infection, offering superior pain relief and symptom management.
Clinical Therapeutics
Effectiveness of Mesotherapy in Post-COVID Pain Syndrome: Retrospective Cohort Study of 96 Patients
İlknur Topal and Onur Yılmaz
Comments (0)